Business Wire

BOEHRINGER-INGELHEIM

Share
Time is of the Essence for Millions Living with ‘Neglected’ Lung Disease: Your Time Campaign Calls for Earlier Action in COPD

Boehringer Ingelheim today announced the launch of the Your Time campaign – a worldwide call to raise public awareness of chronic obstructive pulmonary disease (COPD) and the importance of acting now. By diagnosing and optimally managing the disease earlier it’s still possible to make a real difference to patients’ lives. Despite the disease affecting 210 million people worldwide5 and being responsible for twice as many deaths as diabetes,6 it is little known or talked about. By the time most people know they have COPD, they will have already lost around 50% of their lung function2,3 – and urgent, optimal management is necessary. Identifying and optimally managing COPD in the early stages has the potential to slow the progression of the disease4 and may give patients the best opportunity of living a better life for longer. The Your Time campaign echoes the context of this year’s World COPD Day (18 November 2015), organised by GOLD* around the theme “It’s Not Too Late ”.7

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20151116006198/en/

“COPD has significant physical and emotional impacts on patients. Both patients and healthcare professionals need to be alert to the early signs of COPD, when much of the damage to a patient’s lungs occurs. When COPD is first suspected, I would like to see the same sense of urgency as we give to the first signs of cancer,” said Dr. Richard Russell, consultant respiratory physician, Lymington New Forest Hospital, Hampshire and Senior Clinical Researcher, University of Oxford.

“Increasing awareness of the condition, and the need to tackle it early, is both urgent and important. Effective, early management could mean that people with COPD are more able to maintain a normal active life - such as walking upstairs without stopping, going out to socialise with family and friends or finding it easier to continue doing the things that they enjoy,” Dr Russell continued.

COPD is not only a personal challenge but also a growing challenge for public health. It is the only major cause of death where incidence is increasing and the World Health Organization (WHO) predict that by 2030 COPD will be the 3rd leading cause of death worldwide1 - exceeded only by heart diseases and stroke. In Europe, the annual costs of healthcare and lost productivity due to COPD are estimated as €48.4 billion euros.8

Find out more about the Your Time campaign at www.yourtimeCOPD.com

Making Twitter #COUGH

As part of a drive to raise awareness of COPD and the importance of identifying and diagnosing the disease early, on World COPD Day 2015 Boehringer Ingelheim is aiming to make Twitter #COUGH. As the world #COUGHs the hashtag will produce a noisy spike in Tweets, simulating the sound wave of a COPD sufferer’s chronic cough – a key symptom of the disease.

Look out for and share Tweets with #COUGH this World COPD Day, 18 November to raise awareness and encourage people to act now on COPD.

About COPD

COPD is a progressive, treatable but incurable lung disease. For people with COPD, lung damage causes breathlessness that makes it difficult to keep active and participate in life to the extent they would love to. This can lead to a ‘downward spiral’ of worsening symptoms and even further inactivity,9 contributing to an increased risk of disability and death.10 Optimal management to maintain patients’ quality of life has been shown to significantly reduce their likelihood of having an exacerbation (sudden worsening) of COPD symptoms or being admitted to hospital.11,12

European COPD Coalition: Call to Action on COPD

Boehringer Ingelheim supports the European COPD Coalition’s Call to Action on COPD which seeks political impetus to put in place an EU COPD framework to improve the health and quality of life of European citizens, including persons at risk of, or affected by, COPD.

To find out more and sign the petition visit www.copdcoalition.eu

For ‘Notes to Editors’ and ‘References’ please visit:

http://www.boehringer-ingelheim.com/news/news_releases/press_releases/2015/17_november_2015_copd.html

More information

www.boehringer-ingelheim.com

* Global Initiative for Chronic Obstructive Lung Disease

./ContentItem/Format

#YourTime launch calls for early action to make a real difference to life of #COPD #patients. www.yourtimeCOPD.com

Contact:

Boehringer Ingelheim
Corporate Communications
Media + PR
Dr Kristin Jakobs
Phone: +49 6132 77 144553
Fax: +49 6132 77 6601
Email: press@boehringer-ingelheim.com

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

RTL Luxembourg Expands Deployment of Verimatrix Technologies to Protect Premier Auto Racing Against Piracy11.9.2025 17:45:00 CEST | Press release

RTL’s high-value motorsport racing content now harnesses Verimatrix Counterspy, Deepscan and Watermarking solutions to put them fully in control of their content Regulatory News: Verimatrix, (Euronext Paris: VMX), a leading provider of security solutions for a safer connected world, today announced that RTL Luxembourg, the country’s leading media company, has further expanded its use of Verimatrix anti-piracy tools to now include the full Streamkeeper suite of solutions. Initially deploying Streamkeeper Multi-DRM, RTL Luxembourg also recently implemented Counterspy, Deepscan and Watermarking solutions – the industry’s latest set of powerful tools that help further bolster proactive protections for RTL’s motorsport content revenue. It was announced in April 2024 that RTL Luxembourg selected Verimatrix Streamkeeper Multi-DRM to ensure that RTL Luxembourg remained in full control of its valuable digital assets while also consistently keeping costs low and preventing unneeded technical com

Xylem and Amazon Partner on Smart Water Upgrades to Save More Than 1.3 Billion Liters Annually in Mexico11.9.2025 16:00:00 CEST | Press release

Advanced water technology helps Mexico City and Monterrey reduce leaks and improve supply for thousands of residents Residents in Mexico City and Monterrey will soon enjoy more reliable water supply as the two cities launch groundbreaking infrastructure upgrades to save over 1.3 billion liters of water a year – easing pressure from the rapid urbanization and persistent drought conditions that have strained local water systems. The two cities are working in partnership with global water technology company Xylem (NYSE: XYL) and Amazon (NASDAQ: AMZN) to deploy Xylem Vue, an advanced software platform that applies data and analytics to detect leaks, cut water losses and improve residents’ water supply. The projects are estimated to save upwards of 800 million liters of water a year in Mexico City and 560 million liters a year in Monterrey. “In a water-stressed region, where every liter counts, recovering more than a billion liters of water each year is a game-changer,” said Jaime Barba, Ge

HTEC Partners with World Economic Forum11.9.2025 15:56:00 CEST | Press release

HTEC to bring AI expertise to contribute toindustry transformation and real-world outcomes HTEC, a global digital engineering and product development company, has today announced that it has joined the World Economic Forum’s (WEF) Centre for AI Excellence. HTEC will contribute to the community through its expertise and thought leadership to help advance AI adoption and AI innovation across its core industries. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250911910448/en/ HTEC Partners with World Economic Forum to bring AI expertise to help with industry transformation and real-world outcomes WEF’s Centre for AI Excellence is bringing together leading industry organisations and experts to work together to advance the pace and positive impact AI can have in economies and societies. Its goal is to unlock transformative potential in an equitable and human-centered way, which is well aligned with HTEC’s principles and values. A

Alipay Tap! Users Reach 200 Million, Expands to Over 1,000 Scenarios Beyond Payments11.9.2025 15:31:00 CEST | Press release

Alipay Tap! now supports over 1,000 everyday scenarios, making payments and customer interactions faster and simpler with just a tap.The company also launched its first AI-powered payment service in Luckin Coffee’s app, enabling hassle-free ordering and payment via voice commands to AI agents for the first time. Alipay announced today at the 2025 INCLUSION · Conference on the Bund in Shanghai that its QR code-based contactless payment and engagement solution, Alipay Tap!, has rapidly grown its user base to 200 million since its launch in China in June 2024. The milestone comes just months after surpassing 100 million users in April 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250911881010/en/ With Alipay Tap!, users can open a vending machine with a simple tap Designed to be simpler than QR code scanning, Alipay Tap! lets users complete a transaction or access a service by simply tapping their unlocked phone on a mer

Vertex Scientists Awarded the 2025 Lasker~DeBakey Clinical Medical Research Award for Pioneering Discoveries in Cystic Fibrosis11.9.2025 15:05:00 CEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Senior Vice President Paul Negulescu has been named as one of the winners of this year’s Lasker~DeBakey Clinical Medical Research Award for his role “in the development of a novel, life-saving treatment for cystic fibrosis (CF) — namely, a triple-drug combination therapy, TRIKAFTA®, that has helped countless people with this genetic disease.” Dr. Negulescu is one of three awardees, alongside Jesús (Tito) González, a former Vertex scientist, and Michael Welsh, Professor of Internal Medicine-Pulmonary, Critical Care and Occupational Medicine, University of Iowa. The prize honors the groundbreaking work of Dr. Negulescu, Dr. González and the entire Vertex team who discovered and developed the first and only approved medicines that address the underlying cause of CF. To date, Vertex has brought five transformational medicines to patients with CF which have fundamentally changed the way this disease is treated. “I’m hon

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye